VRDN News and Press, Viridian Therapeutics Inc Com From 06/10/24

2024-06-10 21:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for VRDN on June 10, 2024 07:02PM ET. VRDN was trading at $12.22 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 7 - Buy, 1 -...

2024-06-10 21:00:04 ET Andy Chen from Wolfe Research issued a price target of $29.00 for VRDN on 2024-06-10 19:02:00. The adjusted price target was set to $29.00. At the time of the announcement, VRDN was trading at $12.22. The overall price target consensus is at $36.00...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in June: Je...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May: 202...

2024-05-08 14:27:10 ET Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Louisa Stone – Manager of Investor Relations Steve Mahoney – President and CEO Tom Ciulla – Chief Medical O...

2024-05-08 07:22:53 ET More on Viridian Therapeutics Seeking Alpha’s Quant Rating on Viridian Therapeutics Historical earnings data for Viridian Therapeutics Financial information for Viridian Therapeutics Read the full article on Seeking Alpha ...

- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track...

2024-05-07 11:20:38 ET More on Viridian Therapeutics Seeking Alpha’s Quant Rating on Viridian Therapeutics Historical earnings data for Viridian Therapeutics Financial information for Viridian Therapeutics Read the full article on Seeking Alpha ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 20...

2024-04-25 12:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...